Skip to main content
SpringerLink
Log in

‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent

  • Comment
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

The FDA approval of perioperative pembrolizumab, an approach that combines neoadjuvant and adjuvant therapy with this agent, for patients with early stage non-small-cell lung cancer (NSCLC) contradicts its own stated standard for combination therapies. Given the large population of patients with early stage NSCLC and the high costs of pembrolizumab, whether the adjuvant component provides incremental benefit is an important question.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. US Food and Drug Administration. FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer. fda.gov, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-adjuvant-pembrolizumab-resectable-non-small-cell-lung-cancer (2023).

  2. US Food and Drug Administration. FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. fda.gov, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung (2022).

  3. Strohbehn, G. W., Kacew, A. J., Goldstein, D. A., Feldman, R. C. & Ratain, M. J. Combination therapy patents: a new front in evergreening. Nat. Biotechnol. 39, 1504–1510 (2021).

    Article  CAS  PubMed  Google Scholar 

  4. Theoret, M. Selected regulatory considerations for cancer immunotherapeutic combinations: contribution of individual components to effect of combination. nationalacademies.org, https://www.nationalacademies.org/documents/embed/link/LF2255DA3DD1C41C0A42D3BEF0989ACAECE3053A6A9B/file/DB9638AC5DA89CA34A0EF877A87AFF4EFFE659FF9F3C?noSaveAs=1 (accessed 14 December 2023).

  5. Eun, Y. et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci. Rep. 9, 14039 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  6. US Food and Drug Administration. FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer. fda.gov, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-non-small-cell-lung-cancer (2023).

  7. Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973–1985 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wakelee, H. et al. Perioperative pembrolizumab for early-stage non–small-cell lung cancer. N. Engl. J. Med. 389, 491–503 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Centers for Medicare and Medicaid Services. Medicare Part B Drug Spending Dashboard. cms.gov, https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/information-on-prescription-drugs/medicarepartb (2020).

  10. Strohbehn, G. W., Lichter, A. S. & Ratain, M. J. US government payer-funded trials to address oncology’s drug-dosing conundrum: a congressional call to action? J. Clin. Oncol. 41, 2488–2492 (2023).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

G.W.S. is an employee of the US Department of Veterans Affairs; the opinions expressed herein are the authors’ and do not necessarily reflect those of the US Government. The authors would like to acknowledge H. J. West of Summit Therapeutics for helpful and engaging discussions on this topic. B.G. receives salary support from Ontario Institute for Cancer Research, funded by the Government of Ontario; the opinions expressed herein are the authors’ and do not necessarily reflect those of the Government of Ontario.

Author information

Authors and Affiliations

  1. Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA

    Garth W. Strohbehn

  2. Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA

    Garth W. Strohbehn

  3. Institute for Health Policy and Innovation, University of Michigan, Ann Arbor, MI, USA

    Garth W. Strohbehn

  4. Department of Oncology, Division of Cancer Care and Epidemiology, Queen’s University, Kingston, Ontario, Canada

    Bishal Gyawali

Authors
  1. Garth W. Strohbehn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bishal Gyawali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Garth W. Strohbehn.

Ethics declarations

Competing interests

G.W.S. has acted as a consultant of EBSCO Information Systems and VIVIO Health and is listed as an inventor/co-inventor on patents related to dose optimization technologies and is the director of the Optimal Cancer Care Alliance, an Ann Arbor, MI, USA-based 501(c)3 non-profit organization. B.G. has acted as a consultant of VIVIO Health.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strohbehn, G.W., Gyawali, B. ‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent. Nat Rev Clin Oncol 21, 249–250 (2024). https://doi.org/10.1038/s41571-023-00857-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00857-9

  • Springer Nature Limited

Search

Navigation